Invasive pulmonary aspergillosis after COVID-19

Invasive aspergillosis is a disease that occurs mostly in people with a compromised immune system. The most important pathogen is Aspergillus fumigatus (it accounts for about 90% of the patients). The risk group includes patients who have primary and secondary immunodeficiencies, people receiving immunosuppressive therapy, cancer patients, etc. However, the incidence of this disease among COVID-19 (COronaVIrus Disease 2019) patients have been reported recently. The aim of our work is to present a patient with invasive aspergillosis after COVID-19 who was not in a standard risk group and did not receive immunosuppressive therapy. Conclusion. Patients who had COVID-19 are under a risk of developing invasive pulmonary aspergillosis. Therefore, it is important to exclude this disease in a patient with prolonged pneumonia that does not respond to standard therapy.

1. Ledoux M.P., Herbrecht R. Invasive pulmonary Aspergillosis. J. Fungi (Basel). 2023; 9 (2): 131. DOI: 10.3390/jof9020131.

2. Zakaria A., Osman M., Dabboussi F. et al. Recent trends in the epidemiology, diagnosis, treatment, and mechanisms of resistance in clinical Aspergillus species: a general review with a special focus on the Middle Eastern and North African region. J. Infect. Public. Health. 2020; 13 (1): 1–10. DOI: 10.1016/j.jiph.2019.08.007.

3. Boyer J., Feys S., Zsifkovits I. et al. Treatment of invasive Aspergillosis: how it's going, where it's heading. Mycopathologia. 2023; 188 (5): 667–681. DOI: 10.1007/s11046-023-00727-z.

4. Gangneux J.P., Dannaoui E., Fekkar A. et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir. Med. 2022; 10 (2): 180–190. DOI: 10.1016/S2213-2600(21)00442-2.

5. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. DOI: 10.13140/RG.2.2.31126.63040.

6. Lu L.Y., Lee H.M., Burke A. et al. Prevalence, risk factors, clinical features, and outcome of influenza-associated pulmonary Aspergillosis in critically Ill patients: a systematic review and meta-analysis. Chest. 2024; 165 (3): 540–558. DOI: 10.1016/j.chest.2023.09.019.

7. Ghizlane E.A., Manal M., Abderrahim E.K. et al. Lymphopenia in COVID-19: a single center retrospective study of 589 cases. Ann. Med. Surg. (Lond.). 2021; 69: 102816. DOI: 10.1016/j.amsu.2021.102816.

8. Liu K., Fang Y.Y., Deng Y. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. (Engl.). 2020; 133 (9): 1025–1031. DOI: 10.1097/CM9.0000000000000744.

9. Bhaskar S., Sinha A., Banach M. et al. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front. Immunol. 2020; 11: 1648. DOI: 10.3389/fimmu.2020.01648.

10. Lucas R.M., Liu L., Curson J.E.B. et al. SCIMP is a spatiotemporal transmembrane scaffold for Erk1/2 to direct pro-inflammatory signaling in TLR-activated macrophages. Cell. Rep. 2021; 36 (10): 109662. DOI: 10.1016/j.celrep.2021.109662.

11. Chang T., Yang J., Deng H. et al. Depletion and dysfunction of dendritic cells: Understanding SARS-CoV-2 infection. Front. Immunol. 2022; 13: 843342. DOI: 10.3389/fimmu.2022.843342.

12. Salazar F., Bignell E., Brown G.D. et al. Pathogenesis of respiratory viral and fungal coinfections. Clin. Microbiol. Rev. 2022; 35 (1): e0009421. DOI: 10.1128/CMR.00094-21.

13. Weiss E., Schlegel J., Terpitz U. et al. Reconstituting NK cells after allogeneic stem cell transplantation show impaired response to the fungal pathogen Aspergillus fumigatus. Front. Immunol. 2020; 11: 2117. DOI: 10.3389/fimmu.2020.02117.

14. Schmidt S., Luckowitsch M., Hogardt M., Lehrnbecher T. Natural killer cell line NK-92-mediated damage of medically important fungi. J. Fungi (Basel). 2021; 7 (2): 144. DOI: 10.3390/jof7020144.

15. Soe W.M., Lim J.H.J., Williams D.L. et al. Using expanded natural killer cells as therapy for invasive Aspergillosis. J. Fungi (Basel). 2020; 6 (4): 231. DOI: 10.3390/jof6040231.

16. Morton C.O., Griffiths J.S., Loeffler J. et al. Defective antifungal immunity in patients with COVID-19. Front. Immunol. 2022; 13: 1080822. DOI: 10.3389/fimmu.2022.1080822.

17. Yakovlev S.V., Briko N.I., Sidorenko S.V., Protsenko D.N., eds. [The SCAT program (Antimicrobial Therapy Control Strategy) in the provision of inpatient medical care: Russian clinical guidelines]. Moscow: Pero; 2018. Available at: https://antimicrob.net/wp-content/uploads/skat.pdf?ysclid=lxm7jn9ns3872135974 [Accessed: February 16, 2024] (in Russian).